Kyntra Bio (KYNB) Q2 FY26 earnings call

Kyntra Bio advanced its key clinical programs in Q2 FY26, with FG3246 on track for interim Phase 2 results and Roxadustat's Phase III protocol finalized for a Q4 2026 initiation. The company reported improved net income and maintains a strong cash runway, supporting its strategic vision. Management is pursuing parallel paths for Roxadustat's development, balancing internal funding needs with potential strategic partnerships.